

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Fellowships in Kidney, Urology, and Hematology DDK-G Fellowships in Kidney, Urology, and Hematology.

*Date:* June 12, 2024.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015 (In-Person).

*Contact Person:* Xiaodu Guo, M.D., Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7023, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-4719, [guox@extra.nidk.nih.gov](mailto:guox@extra.nidk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology

and Hematology Research, National Institutes of Health, HHS)

Dated: April 2, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-07279 Filed 4-4-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.


**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.

**FOR FURTHER INFORMATION CONTACT:** Licensing information may be obtained by contacting Michael Shmilovich, Esq, MS, CLP; 301-435-5019; [michael.shmilovich@nih.gov](mailto:michael.shmilovich@nih.gov), at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29,

MSC2479, Bethesda, MD 20892-2479. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

**SUPPLEMENTARY INFORMATION:** This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404. Technology description follows. Prazole-Based Antiviral Therapeutics:

Available for licensing and commercial development is a patent estate that covers prazole based compounds and their methods of use as antiviral therapeutics. Prazoles are benzimidazole derivatives generally marketed as stomach-acid reducers, owing to their ability to inhibit the H+/K+ ATPases (proton pumps) of the parietal cells in the stomach epithelium. Prazoles can inhibit the egress of several viral targets: HIV-1, HSV-1 and -2, MAYV, and EBV by interfering with the ESCRT complex in the formation of exosomes. In that respect, the target for inhibition of these viruses is Tumor susceptibility gene 101 (Tsg101), a member of the ESCRT-I complex. The N-terminal ubiquitin E2 variant (UEV) domain of Tsg101 has both ubiquitin and P[T/S]AP motif binding sites, where the prazole binds to C73 in the middle of the ubiquitin-binding site, sterically inhibiting the Ub-Tsg101 interaction. By way of example, and not limitation, a prazole compound according to this invention can take on the follow core structure:



Where L is optionally present and is a C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>- group where n is an integer from 1 to 6, a phenyl group, or a benzyl group, each of which is optionally substituted. B is a substituted or unsubstituted aromatic or heteroaromatic substituent, and where

X<sub>1</sub> is S(=O) or S;

Y<sub>1</sub> is N or CR<sub>4</sub>; and

each of R<sub>1</sub>-R<sub>7</sub> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, perfluoro C<sub>1</sub>-C<sub>6</sub> alkyl, perfluoro C<sub>1</sub>-C<sub>6</sub> alkoxy, halo, -CN, -OH, -COOR<sub>s</sub>, substituted or unsubstituted aromatic, or substituted or unsubstituted heteroaromatic, and

each R<sub>8</sub> independently is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, or benzyl.

*Potential Commercial Applications:*

- antivirals
- therapeutics
- ESCRT complex formation
- prazole
- antifungal

*Development Stage:*

- Early stage

*Inventors:* Nico Tjandra (NHLBI), Carol Carter (Stonybrook), Rolf E. Swenson (NHLBI), David Nyenhuis (NHLBI), Natarajan Raju (NHLBI), Chandra Mushti, (NHLBI), and Venkata Sabbasani (NHLBI).

*Intellectual Property:* HHS Reference No. E-239-2023-0; U.S. Provisional Patent Application No. 63/545,080 filed October 20, 2023.

*Publication:* D. A. Nyenhuis, S. Watanabe, R. Bernstein, R. E. Swenson,

N. Raju, V. R. Sabbasani, C. Mushti, D.-Y. Lee, C. Carter, N. Tjandra, "Structural Relationships to Efficacy for Prazole-Derived Antivirals." *Adv. Sci.* 2024, 2308312. <https://doi.org/10.1002/advs.202308312>.

*Licensing Contact:* Michael Shmilovich, Esq, MS, CLP; 301-435-5019; [michael.shmilovich@nih.gov](mailto:michael.shmilovich@nih.gov).

Dated: April 2, 2024.

**Michael A. Shmilovich,**

*Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.*

[FR Doc. 2024-07278 Filed 4-4-24; 8:45 am]

**BILLING CODE 4140-01-P**